Psyence Group Inc. (PSYGF)
USD 0.03
(258.67%)
USD 0.03
(258.67%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 11.29 Million CAD | 585.75% |
| 2023 | -2.33 Million CAD | -7.84% |
| 2022 | -2.16 Million CAD | -5435.71% |
| 2021 | -39.13 Thousand CAD | 72.19% |
| 2020 | -140.73 Thousand CAD | 18.75% |
| 2019 | -173.22 Thousand CAD | -24126.57% |
| 2018 | -715.00 CAD | 10.06% |
| 2017 | -795.00 CAD | 0.0% |
| 2016 | -795.00 CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | 11.29 Million CAD | 583.61% |
| 2024 Q4 | 11.29 Million CAD | 5471.02% |
| 2024 Q1 | -683.24 Thousand CAD | 70.76% |
| 2024 Q3 | -210.35 Thousand CAD | -246.82% |
| 2024 Q2 | 143.27 Thousand CAD | 120.97% |
| 2023 Q2 | -62.47 Thousand CAD | 93.7% |
| 2023 FY | -2.33 Million CAD | -7.84% |
| 2023 Q4 | -2.33 Million CAD | -297.09% |
| 2023 Q3 | -588.34 Thousand CAD | -841.79% |
| 2023 Q1 | -992.22 Thousand CAD | 54.2% |
| 2022 Q3 | -3.32 Million CAD | 20.16% |
| 2022 FY | -2.16 Million CAD | -5435.71% |
| 2022 Q1 | -5.25 Million CAD | -86838.57% |
| 2022 Q4 | -2.16 Million CAD | 34.82% |
| 2022 Q2 | -4.16 Million CAD | 20.74% |
| 2021 Q2 | -115.65 Thousand CAD | 0.0% |
| 2021 FY | -39.13 Thousand CAD | 72.19% |
| 2021 Q4 | -6041.45 CAD | 95.15% |
| 2021 Q3 | -124.5 Thousand CAD | -7.66% |
| 2020 FY | -140.73 Thousand CAD | 18.75% |
| 2019 FY | -173.22 Thousand CAD | -24126.57% |
| 2018 FY | -715.00 CAD | 10.06% |
| 2017 FY | -795.00 CAD | 0.0% |
| 2016 FY | -795.00 CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.74 Billion USD | 99.95% |
| Bristol-Myers Squibb Company PFD CONV 2 | 30 Billion USD | 99.962% |
| CSPC Pharmaceutical Group Limited | -1.59 Billion USD | 100.709% |
| Clarus Therapeutics Holdings, Inc. | 15.85 Million USD | 28.735% |
| Novartis AG | 12.95 Billion USD | 99.913% |
| PT Kalbe Farma Tbk. | -169.7 Million USD | 106.658% |